Leerink Partners reiterates Henry Schein stock rating at $87 target By Investing.com

Henry Schein reported Q4 2025 EPS of $1.34 vs $1.30 est (+$0.04) and revenue of $3.40B vs $3.34B est (+$60M). Leerink reiterated a Market Perform with a $87 PT (current $77.10, ~13% upside) but says most improvement is priced in and remains cautious on the dental-market recovery; the company is investing in AI via an AWS partnership and nine analysts have recently cut earnings estimates.

Analysis

Henry Schein’s equipment outperformance is not just a revenue beat — it changes downstream OEM allocation and dealer dynamics. If HSIC continues to take incremental share in higher-ticket digital equipment (scanners, 3D printers), suppliers will prioritize its distribution lanes, creating a feedback loop that squeezes peers’ fill rates and raises HSIC’s average order value and aftermarket service revenue over 6–18 months.

The AWS/AI investment is a multi-year operating lever rather than a one-off tech press release: properly executed it can compress SG&A and shrink days-in-inventory through demand forecasting, reorder automation and remote diagnostics, converting working capital into recurring software-like gross margins. Offsetting this upside are usage-based cloud costs and integration risk — heavy initial data labeling and clinician workflow change-management could keep incremental margins negative for 2–4 quarters.

Primary downside catalysts are macro-driven elective-care softness and execution slippage on AI rollouts; both can reverse multiple expansion quickly because much of the improvement appears priced in. Watch quarterly guidance cadence, same-store procedure volumes, OEM lead-times, and incremental gross margin from software services as 30–90 day tell signals for trajectory change.

Key Decisions for Investors

• Pair trade (12–18 months): Long HSIC vs short PDCO, equal notional. Rationale: isolate share gains from market cyclicality — expect 20–30% relative upside if HSIC’s equipment share and software uplift materialize; stop-loss: 12% on the pair if both move down in lockstep, take profits at 15–20% relative outperformance.
• Directional, limited-risk options (18 months): Buy HSIC Jan 2027 $90 calls and sell HSIC Jan 2027 $120 calls (debit call spread). Entry on <8% pullback or immediately to lock multi-year AI optionality; capped downside = premium paid, upside = spread width minus premium (~3–4x potential return if spread narrows favorably).
• Tactical income for holders (90–180 days): If already long stock, sell 6–9 month covered calls at ~10–15% OTM to monetize near-term optimism that’s likely priced in. This reduces upside but generates yield if guidance disappoints; roll on signs of material AI adoption or higher procedure volume.
• Event hedge (3–6 months): Buy HSIC put protection or inexpensive put calendar (near-term put + longer-term sell) ahead of next quarterly guide if you own the stock — protects against a sudden dental-demand reversal while keeping some carry if recovery stalls.